Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Brimonidine Formulations in Glaucoma
NCT00168363Phase 3Completed
- Sponsor
- Allergan
- Start
- Jan 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of brimonidine in Glaucoma and ocular hypertension (2 arms), sponsored by Allergan. Primary endpoint: Intraocular Pressure at 12 months. Started Jan 2005; status: completed.
02
Drugs
brimonidine
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT00168363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168363.